

COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS

pursuant to Article 85-bis, paragraph 4-bis, of Consob Regulation no. 11971/1999

Saluggia, June 7th, 2023 – DiaSorin S.p.A. (“DiaSorin” or the “Company”) hereby announces that today two shareholders, holding equity interests lower than 3% of the overall voting rights – having fulfilled the requirements and conditions under the applicable regulation and the Company By-Laws – obtained the assignment of increased voting rights (based on the ratio of two votes for each share) for overall no. 58,556 ordinary shares of the Company.

It is also announced that one shareholder, holding equity interests lower than 3% of the overall voting rights, waived to the increased voting rights already accrued for overall no. 14,000 ordinary shares of the Company.

In accordance with Article 85-bis paragraph 4-bis, of Consob Regulation no. 11971/1999, the total amount of the voting rights is presented below, together with the number of shares making up the share capital:

	Status after assignment of increased voting rights			Status before assignment of increased voting rights		
	Number of shares making up share capital	No. of voting rights	Euro	Number of shares making up share capital	No. of voting rights	Euro
Total amount, of which:	55,948,257	88,376,827	55,948,257	55,948,257	88,332,271	55,948,257
Ordinary shares without increased voting rights ISIN IT0003492391 (regular dividend) Current coupon: no. 18	23,519,687	23,519,687	-	23,564,243	23,564,243	-
Ordinary shares with increased voting rights ISIN IT0005188385 (regular dividend) Current coupon: no. 18	32,428,570	64,857,140	-	32,384,014	64,768,028	-

The Special List, updated in accordance with Article 9-*quater* of the Company By-Laws, is available on the Company website www.diasoringroup.com, in the Section “Governance/Ownership Structure/Loyalty shares”.



The Diagnostic Specialist

PRESS RELEASE ○○○

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 41 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasoringroup.com

For additional information, please contact:

Riccardo Fava

Corporate Vice President Communication, ESG & Investor Relations
riccardo.fava@diasorin.it

Eugenia Ragazzo

Corporate Investor Relations & ESG Analyst
eugenia.ragazzo@diasorin.it